Related Experiment Videos
The prevention of sudden death in hypertrophic cardiomyopathy
Bhavesh Sachdev1, M Shoaib Hamid, Perry M Elliott
1Department of Cardiological Sciences, St. George's Hospital Medical School, Cranmer Terrace, London, SW17 0RE, UK. pelliott@sghms.ac.uk
Insights
Hypertrophic cardiomyopathy (HCM) is a genetic heart condition leading to sudden cardiac death risk. Identifying high-risk patients is challenging, necessitating improved clinical understanding and risk stratification strategies.
Area of Science:
- Cardiology
- Genetics
- Pathology
Background:
- Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disease.
- It results from mutations in cardiac sarcomeric proteins, causing myocyte disarray and fibrosis.
- Sudden cardiac death is a major complication, but risk identification is difficult due to clinical heterogeneity and absence of symptoms.
Purpose of the Study:
- To highlight the challenges in diagnosing hypertrophic cardiomyopathy patients at risk of sudden cardiac death.
- To emphasize the need for enhanced clinical understanding and risk stratification methods.
Main Methods:
- Review of existing clinical data and understanding of hypertrophic cardiomyopathy.
- Analysis of diagnostic challenges and current risk management strategies.
Main Results:
- Hypertrophic cardiomyopathy presents with significant clinical heterogeneity.
- Current methods for identifying high-risk individuals are insufficient.
- Low-dose amiodarone and internal cardioverter/defibrillator implantation are current options for high-risk patients.
Conclusions:
- Accurate risk stratification for sudden cardiac death in hypertrophic cardiomyopathy remains a significant clinical challenge.
- Further research is essential to improve the identification of at-risk individuals.
- Improved diagnostic and prognostic tools are needed for better patient management.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a familial myocardial disease caused by mutations in cardiac sarcomeric proteins. HCM is characterised by myocyte disarray and myocardial fibrosis. Most patients are largely asymptomatic but some are prone to a number of disease-related complications, the most problematic of which is sudden cardiac death. Diagnosing patients who are at risk has not been easy because of the clinical heterogeneity of the disease, the frequent absence of symptoms prior to sudden cardiac death and the relatively low disease prevalence and annual mortality rates. To date, both low-dose amiodarone and internal cardioverter/defibrillator implantation have been advocated in high-risk individuals. Further improvements in clinical understanding and risk stratification are necessary to identify HCM patients who are at high risk of sudden death.